199 results about "Alanine aminotransferase" patented technology

The present invention is reducing nicotine amide coenzyme as enzyme testing reagent for testing body fluid. The enzyme testing reagent of the present invention includes oxidizing nicotine amide coenzyme, corresponding enzyme and substrate. The oxidizing coenzyme is reduced into reducing nicotine amide coenzyme slowly to test the tested matter. The reagent includes alanine aminotransferase reagent, aspartic acid aminotransferase reagent, urea reagent, ammonia reagent, creatinine reagent, CO2 reagent, etc. Owing to constant creation of nicotine amide coenzyme, the present invention has greatly raised reagent stability and greatly lowered reagent cost.

Methods of increasing nitrogen utilization efficiency in monocot plants through genetic modification to increase the levels of alanine aminotransferase expression and plants produced there from are described. In particular, methods for increasing the biomass and yield of transgenic monocot plants grown under nitrogen limiting conditions compared to non-transgenic plants are described. In this way, monocot plants may be produced that maintain a desired yield while reducing the need for high levels of nitrogen application.

The invention provides a stable composition containing NAD+ or NADH. Bioactivity of NAD+ or NADH can be stably maintained for a long time. By the use of a stabilizer which contains trehalose, glycerol, a buffer solution and a surfactant, stability of NAD+ and NADH dissolved state is raised. The invention also provides a method for stabilizing NAD+ or NADH, and also provides an application of a composition composed of trehalose, glycerol, the buffer solution, the surfactant and a pH regulator in increasing stability of NAD+ or NADH. The composition can be used for a lactate dehydrogenase reagent, an alanine aminotransferase reagent, an aspartate aminotransferase reagent, a urea kid and the like, and is widely applied.

The present invention relates to a compound of Antrodia camphorata used for liver protection, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata. The cyclohexenone compound according to the invention helps to alleviate liver injury and fibrosis induced by chemicals and reduces the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). By increasing the contents of glutathione peroxidase (GSHPx) and catalase (CAT), cyclohexenone further decreases the liver damage and the oxidative pressure caused by free radicals, enhances the antioxidant ability and achieves the purposed of liver protection.

The present invention relates to an altered-type human ALT gene in which the codons for the five amino acids in the human ALT (alanine aminotransferase) gene are replaced, i. e. the fourth amino acid codon from the initiation codon for methionine (Met) is replaced by a codon for serine (Ser), the fifth by a codon for threonine (Thr), the seventh by a codon for aspartic acid (Asp), the 39th by a codon for glycine (Gly) and the 222nd by a codon for alanine (Ala), and concurrently, restriction sites are added at the upstream and downstream of said gene.The active human ALT having properties similar to those of the native enzyme can be effectively produced by culturing E. coli transformed with a recombinant plasmid in which the altered-type human ALT gene of the present invention is ligated to a vector.

The invention discloses an interference-removing dry chemical quantitative test strip. The strip comprises a bottom liner, wherein the bottom liner is provided with a sample addition region and also a starting region; the sample addition region is fixed with interference-removing reagents and signal providing reagents; the starting region is fixed with test reaction starting reagents; and the sample addition region and the starting region are arranged on the test strip in a mode of maintaining a non-contact under a normal state and mutually contacting under a test state. The test method comprises the following steps of: adding a sample solution to be tested into the sample addition region, re-dissolving materials fixed on the sample addition region into the sample solution to be tested, and starting to perform a signal reaction to obtain a background signal value; and then enabling the starting region to contact with the sample addition region, re-dissolving materials fixed on the starting region, starting a test reaction, performing a second-time signal reaction on a product again, and estimating out a content of a biological enzyme to be tested according to a tested second-time characteristic value and the background signal value. The test method provided by the invention has the advantages of convenience for operation, low test cost, accurate test result and high test precision and can specifically be used in the alanine and aspartate aminotransferase quantitative test.

The present invention provides a method capable of producing a natural or recombinant protein in high yield.The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.

The invention discloses a measuring method of Alanine Aminotransferase (ALT) and agent box in the external diagnostic technical domain, which comprises the following steps: reacting agent 1 and sample; generating hydrogen peroxide through reacting acetonic acid oxidase and endogenous acetonic acid; producing water and oxygen from hydrogen peroxide acted by catalase; reacting with agent 2; utilizing L-Ala and alpha-ketoglutaric acid starting serum ALT to react; detecting the activity of serum ALT of absorbance change of linear reaction.

The invention discloses hepatic fibrosis detection system, relating to the technical field of hepatic fibrosis research. The hepatic fibrosis detection system comprises a transient elastography device an input device, a classifier and an output device, wherein the input device is used for receiving ages and serum biochemical indicators, and the serum biochemical indicators at least comprise blood platelet, hyaluronic acid (HA), serum direct bilirubin (DBIL), prothrombin time (PT), alanine aminotransferase / serum glutamic pyruvic transaminase (ALT; GPT), and aspartate transaminase / serum glutamic oxalacetic transaminase (AST; GOT); the classifier is used for performing hepatic fibrosis staging according to the ages and the serum biochemical indicators and received by the input device and transient elasticity imaging data; and the output device is used for outputting of hepatic fibrosis staging results of the classifier. The hepatic fibrosis detection system of the embodiment disclosed by the invention has the advantages of noninvasiveness, strong practicability, simple and convenient method, low price, good safety and the like.

The invention discloses a method for extracting coreopsis tinctoria procyanidins and an application of the coreopsis tinctoria procyanidins in delaying senescence. The method comprises the following steps: extracting coreopsis tinctoria procyanidins from the raw material coreopsis tinctoria which grows 2600m over the sea level by adopting a dynamic high-pressure microfluidization assisted extraction technology for 30 minutes with 70% ethanol at the extracting pressure of 120MPa and the extracting temperature of 50 DEG C, and treating the coreopsis tinctoria twice by means of microjet pressure. The total antioxidation activity of the prepared procyanidins is higher than that of ascorbic acid, and has an effect of delaying senescence of drosophila melanogaster by combining results of drosophila melanogaster surviving experiments and in-vivo biochemical index detection; liver injury experiments in mice indicate that the procyanidins extracted from coreopsis tinctoria is capable of reducing the activities of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) in serum and playing a certain role in protecting CC14 caused liver injury in mice. According to the application, the procyanidins extracted from coreopsis tinctoria have an excellent effect of delaying senescence, and has a wide practical value.

The invention relates to an alanine aminotransferase (ALT) detection kit, belongs to the technical field of clinical in vitro diagnostic reagents, and aims at being capable of providing an alanine aminotransferase detection kit which can effectively eliminate interference of endogenous alpha-ketoglutaric acid and is good in stability to enable an alanine aminotransferase determination result to be more accurate and reliable. The kit comprises a reagent 1 and a reagent 2, wherein the reagent 1 is prepared from a Tris-HCl buffer solution, L-alanine, a reduced coenzyme (NADH), lactic dehydrogenase (LDH), an enzyme protectant, a stabilizer and a preservative, and the reagent 2 is prepared from a Tris-HCl buffer solution, alpha-ketoglutaric acid, a stabilizer and a preservative. Due to the fact that the enzyme protectant and the stabilizer are added into the ALT detection kit, the stability of the alanine aminotransferase detection kit is improved, and the alanine aminotransferase (ALT) detection kit is suitable for various full-automatic biochemical analyzers, easy to operate, safe in operation and convenient to apply and popularize clinically.

The invention discloses a blood alanine aminotransferase detecting reagent with high stability, and belongs to the technical field of clinical in-vitro detection. According to the blood alanine aminotransferase detecting reagent with high stability, disclosed by the invention, the blood serum alanine aminotransferase (ALT) is detected by using the single reagent method on the basis of an enzyme-coupled continuous detection method, so that the problem that the single reagent in the original formula is unstable is solved, and the reagent is simple and convenient to operate, and facilitates clinical application and popularization.

The invention relates to the application of Ilex latifolia total glycosides and a preparation method thereof. Studies finds that the Ilex latifolia total glycosides can reduce the content of malonaldehyde (MDA) and triglyceride (TG) in liver, increase the content of reduced glutathione (GSH) in each dose group of liver, reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in liver, and has alcoholic hepatitis and fatty liver resisting activity. Compared with the prior art, the invention provides a new application of Ilex latifolia total glycosides in preparing drugs and / or functional food for preventing and / or treating alcoholic hepatitis and fatty liver; the invention also provides a preparation method of the Ilex latifolia total glycosides with the advantages of safe and simple process, saved cost, high efficiency, and easy quality control; and the invention further provides a preparation of the Ilex latifolia total glycosides.

The invention relates to an application of broadleaf holly leaf glycosides and a preparation method thereof. Researches show that the broadleaf holly leaf glycosides can lower level of malondialdehyde (MDA) and triglyceride (TG) in liver tissues, increase level of reduced glutathione(GSH) of each dosage group in liver tissues, lower level of Alanine Aminotransferase (ALT) and Aspertate Aminotransferase (AST) in liver tissues; the broadleaf holly leaf glycosides has the activity of anti-alcoholic hepatitis and anti-adiposis hepatica. Compared with the prior art, the invention has the advantages of: 1. providing a new application of broadleaf holly leaf glycosides, in particular to an application on preparing medicines for curing adiposis hepatica and alcoholic hepatitis; 2. providing a preparation method for broadleaf holly leaf glycosides, and the preparation method is safe in production technics, economic in cost, high in efficacy, easy for quality control and more simple in preparation; and 3. providing a preparation of broadleaf holly leaf glycosides.

The invention discloses a combined detection card for blood screening, which includes a card base and a card cover fastened on the card base. The card base is provided with a plurality of card slots parallel to each other; the multiple card slots are divided into sequentially Multiple groups are arranged, and each group of card slots corresponds to the infectious disease detection area, blood type detection area, hemoglobin detection area and alanine aminotransferase detection area in sequence, and each card slot is equipped with a test strip matching its detection area; The card cover is sequentially provided with an observation window, a sampling hole and an auxiliary liquid hole at the positions corresponding to the test strips in the infectious disease detection area on the deck; There are sampling holes and auxiliary liquid holes in sequence on the position; the card cover is opened with a sampling hole at the position corresponding to the test strip in the hemoglobin detection area; the card cover is at the position corresponding to the test strip in the alanine aminotransferase detection area There are observation windows and sample injection holes on the top. The invention can realize the detection of multiple items in one card and can ensure the accuracy of detection.

The invention relates to traditional Chinese medicine composition with functions of relieving alcoholism and protecting the liver. The traditional Chinese medicine composition comprises raw medicinalmaterials as follows: flos puerariae, semen hoveniae, medicated leaven, fructus amomi rotundus, white poria cocos, radix ginseng, raw fructus crataegi, fructus schisandrae chinensis and raw oysters, and the raw medicinal materials are compatible and have the functions of eliminating dampness caused by alcohol and regulating qi-flowing for strengthening spleen. The pharmacological experiment indicates that with the adoption of the traditional Chinese medicine composition, drunkenness latency time of a mouse can be prolonged, drunkenness time of the mouse is shortened, content of alcohol in blood is reduced, level of ALT (alanine aminotransferase), AST (aspartate aminotransferase) and MDA (malondialdehyde) in the liver is reduced, activity of GSH-PX (glutathione peroxidase) and ADH (alcoholdehydrogenase) is improved, and the traditional Chinese medicine composition has excellent effects of relieving alcoholism and protecting the liver.

The invention relates to preparation of standards, and particularly relates to a recombinant human alanine aminotransferase protein standard, a recombinant human aspartate aminotransferase protein standard, and preparation methods thereof. A nucleotide sequence of encoding the recombinant human alanine aminotransferase protein standard is shown in SEQ ID NO:3; the nucleotide sequence of encoding the recombinant human aspartate aminotransferase protein standard is shown in SEQ ID NO:6. The invention also relates to the preparation method of the recombinant human alanine aminotransferase protein standard or the recombinant human aspartate aminotransferase protein standard. The preparation method comprises the following steps: obtaining a target gene; building a gene expression strain; expressing and purifying target protein; processing matrix serum, evaluating the standard, and evaluating a constant value and the uncertainty of the standard. The recombinant human alanine aminotransferase protein standard and the recombinant human aspartate aminotransferase protein standard prepared by adopting a gene recombination technique disclosed by the invention can be applied to clinical test of a laboratory and mass control of a kit.

The invention relates to an application of a novel compound in preparation of liver protection drugs or health care products and further relates to a method for preparing the compound through extraction, separation and purification from Sabia parviflora. The pharmacological research indicates that the novel compound can reduce the content of ALT (alanine aminotransferase) and AST (aspartic transaminase) in serum of a CC14 induced acute liver injury model mouse, a D-galactosamine induced acute liver injury model mouse and an ethanol induced liver injury model mouse, reduce the content of MDA (methylene dioxyamphetamine) in liver tissue and enhance SOD (superoxide dismutase) activity of the liver, has a remarkable protection effect on liver injury and is expected to be developed into new drugs or health care products with the liver protection function.

The invention relates to an extraction method of a kiwi fruit root extract and an anti-liver injury application thereof, belonging to the fields of preparation and application technology of the kiwi fruit root extract. The invention takes kiwi fruit root or root bark as raw material, utilizes ethanol solution for extraction, further separates the extract on a column and extracts to obtain the kiwi fruit root extract containing active ingredients with anti-liver injury effect. The kiwi fruit root extract can significantly reduce alanine aminotransferase ALT in plasma of mice with acute carbon tetrachloride-induced liver injury, the decreasing range achieves 64.72 percent, which is greater than the effect of ammonium glycyrrhizinate, the kiwi fruit root extract can also significantly reduce serum aspartate aminotransferase AST, the decreasing range achieves 28.26 percent, which is not as good as the effect of the ammonium glycyrrhizinate. The invention provides a new valuable use for comprehensively utilizing the kiwi fruit root.

The invention is applicable to the field of Chinese patent medicines. A lipopolysaccharide-induced rat diffuse intravascular coagulation model is adopted for experimenting, and the experiment result shows that a compound thrombosis capsule can significantly inhibit the rise of liver-function biochemical indexes of aspartate aminotransferase and alanine aminotransferase, reduces the level of lipopolysaccharide-induced liver inflammation, and reduces congestion and hemorrhage phenomena in liver veins, namely finding out the new application of the compound thrombosis capsule playing a role of protecting the liver.

The invention relates to a method for producing sea cucumber bio-alcohol. The method has the following characteristics that: sea cucumber is soaked in water, the produced soak is centrifugally filtered and concentrated, the produced concentrated solution is cooled, fucoidan hydrolytic enzyme is added to enzymatically hydrolyze the fucoidan in the concentrated solution, the temperature is increased to 80 DEG C to 90 DEG C, so that the fucoidan hydrolytic enzyme is inactivated, the produced enzymatically hydrolyzed solution is filtered, edible alcohol and auxiliary materials are added and blended, and the produced sea cucumber bio-alcohol is filtered by diatomite, filled, sterilized and packed. The sea cucumber bio-alcohol can increase the pH value of the acidic body fluid of the human body, enhance the activity of insulin, repair islet cells injured by the acidic constitution, recover the normal functions of islet cells and effectively reduce postprandial plasma glucose; and the sea cucumber bio-alcohol can strengthen metabolism, improve the acidic constitution, stabilize blood pressure, reduce blood sugar, blood fat, blood viscosity and the like, prevent and improve diabetes complication, notably reduce the activity of liver-injuring serum alanine aminotransferase and aspartate aminotransferase, increase the activity of liver SOD and reduce the content of MDA, thus having the function of protecting the liver.

Disclosed is a stabilized enzyme composition for use in clinical examination, comprising: (a) an enzyme component comprising at least two enzymes selected from the group consisting of alkaline phosphatase, creatine kinase and alanine aminotransferase; (b) a stabilizer component comprising effective stabilizing amounts of an albumin, and at least one saccharide selected from the group consisting of trehalose and sorbitol; and (c) an aqueous medium having dissolved therein the components (a) and (b). The enzyme composition of the present invention is stable for a prolonged period of time not only under non-freeze refrigeration conditions, but also under freezing conditions or under conditions for non-freeze refrigeration after thawing of the frozen composition, as compared to the conventional enzymatic compositions. The enzyme composition of the present invention can be advantageously used for the purpose of checking the precision in measurement, correcting measured values and calibrating the amount and activity of an enzyme, in a clinical examination for measuring the enzymatic activity in a sample, such as serum or the like.

Methods are provided by which Oryza sativa plants and seeds thereof may be modified to express a coding region of interest using a promoter sequence operatively linked to the coding region. The promoter sequence is an isolated Oryza sativa antiquitin (OsAnt1) promoter sequence including SEQ ID NO: 1. The coding region of interest may encode a nitrogen utilization protein, suitably alanine aminotransferase. Methods to develop Oryza sativa plants that have increased biomass and seed yield are also presented. Furthermore, Oryza sativa plants may be produced that maintain a desired yield while reducing the need for high levels of nitrogen application.

The invention relates to the field of foods and discloses a formula food suitable for diabetes and a preparation method thereof. The formula food can be a wet or dry formula, wherein the wet formula comprises 100-200g of fresh skim milk, 10-20g of vegetable oil, 10-30g of special protein composition, 10-30g of tea leaf composition, 2-8g of oligosaccharide, 0.4-2g of vitamin premix, 1-4g of mineral premix and the balance of maltodextrin, totaling 100g; and the dry formula comprises 15-30g of skim milk powder, 20-40g of vegetable fat powder, 10-30g of special protein composition, 10-30g of tea leaf composition, 2-8g of oligosaccharide, 0.4-2g of vitamin premix, 1-4g of mineral premix and the balance of maltodextrin, totaling 100g. The formula food disclosed by the invention has obvious effects of regulating blood sugar level, alanine aminotransferase (ALT) and aspartate amino transferase (AST) and has good taste.

The invention discloses a water-soluble fullerene structure for preparing a medicine for treating fatty liver, and discloses a pharmaceutical composition and a method for treating fatty liver. Activeingredients for treating fatty liver are water-soluble fullerene, water-soluble inlaid metal fullerene, composition of the water-soluble fullerene and the water-soluble inlaid metal fullerene, and pharmaceuitical ester of above three and pharmaceutical salt of the three. The active ingredient water-soluble fullerene structure can reduce fatty vesicles in the liver, lower blood lipids, and obviously improve liver function, so that the content of alanine aminotransferase and aspartate aminotransferase tends to be normal, and the effect of treating fatty liver is highly effective. The active ingredient water-soluble fullerene structure can also regulate the level of redox in the liver.

The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.

The invention discloses a buffer solution for human serum alanine aminotransferase measurement, is used in a kit by using Tris-citric acid as a buffer system. The kit comprises a first reagent and a second reagent, wherein the first reagent is composed of Tris, alanine, NADH (nicotinamide adenine dinucleotide), lactate dehydrogenase, sodium azide and citric acid; and the second reagent is composed of Tris, alpha-ketoglutarate, sodium azide and citric acid. The buffer solution for human serum alanine aminotransferase measurement adopts the Tris-citric acid as the buffer system. The buffer solution can provide benign conditions for enzymatic reaction of alanine aminotransferase in human serum; and the matched kit has higher accuracy and stability of measurement data than the existing reported buffer solutions, and thus, is worthy of popularization and application.